ADAPTIVE BIOTECHNOLOGIES CORPORATION APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $3.33 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2021-02-24
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-06-30 was $3.33M, a 36.17% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-03-31 was $3.05M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2018-12-31 was $3.05M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2018-09-30 was $2.55M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2018 was $11.15M, a 61.07% increase from fiscal 2017.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2017 was $6.92M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2019-06-30 | $3.33M 10-Q · filed 2020-08-10 | $6.38M 10-Q · filed 2020-08-10 | $9.42M derived: sum of 3 quarters · filed 2021-02-24 | $11.98M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $3.05M 10-Q · filed 2020-05-12 | $6.09M derived: sum of 2 quarters · filed 2021-02-24 | $8.64M derived: sum of 3 quarters · filed 2021-02-24 | $11.09M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $5.60M derived: sum of 2 quarters · filed 2021-02-24 | $8.05M derived: sum of 3 quarters · filed 2021-02-24 | $11.15M 10-K · filed 2021-02-24 |
| 2018-09-30 | $2.55M 10-Q · filed 2019-11-12 | $5.00M derived: sum of 2 quarters · filed 2019-11-12 | $8.10M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $2.45M 10-Q · filed 2019-08-13 | $5.55M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | $6.92M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |